- BNT327-05, or ROSETTA Breast-01, is a recruiting Phase 3 BioNTech study.
- The study compares investigational pumitamig plus chemotherapy with placebo plus chemotherapy.
- It is designed for selected adults with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer, as well as certain ER-low, HER2-negative breast cancers.
- PD-L1 status, measurable disease, tissue availability, prior treatment, and ECOG performance status are among the important screening factors.
- Pumitamig is investigational and is not approved for prescribing in triple-negative breast cancer.
- Participation cannot guarantee a medical benefit, and site availability can change.
For an adult considering a triple-negative breast cancer clinical trials request, the practical first step is to compare the person’s diagnosis, biomarker results, treatment history, overall health, and travel options with a specific study’s requirements. BioNTech’s triple‑negative breast cancer clinical trials page describes BNT327-05, also called ROSETTA Breast-01, as a recruiting Phase 3 study for selected people with advanced disease.
The study team must review medical records, pathology, scans, laboratory results, and other screening information. A treating oncologist can help determine whether pursuing screening for this investigational option makes sense alongside other care choices.
Why BioNTech Is Studying BNT327-05 in Triple-Negative Breast Cancer
Triple-negative breast cancer, often called TNBC, lacks estrogen receptors, progesterone receptors, and substantial HER2 expression. Because it lacks these biomarkers, treatments directed at hormone receptors or HER2 are not suitable for this cancer type. The National Cancer Institute notes that TNBC represents about 15% of breast cancers and provides broader information about triple-negative breast cancer for patients and caregivers.
Survival statistics describe groups of people, not what will happen to one individual. Stage, tumor biology, treatment response, general health, and other factors can affect an individual’s prognosis.
What Is BioNTech’s BNT327-05 ROSETTA Breast-01 Trial?
ROSETTA Breast-01 is an interventional Phase 3 study sponsored by BioNTech SE. Its trial identifier is BNT327-05, and its ClinicalTrials.gov identifier is NCT07173751. The study is expected to enroll about 558 participants and is listed with an estimated study period from October 2025 through December 2029.
The official study record for NCT07173751 identifies the research as a controlled study of pumitamig with chemotherapy in people with advanced TNBC who are considered ineligible for a monospecific PD(L)1 immunotherapy plus chemotherapy based on tumor PD-L1 status. Pumitamig is also known as BNT327, PM8002, or BMS-986545.
How the Treatment Design Works
Participants are assigned at random, with equal probability, to one of two treatment groups. One group receives pumitamig with chemotherapy, while the other receives a matching placebo with chemotherapy.
The chemotherapy options listed for the study include nab-paclitaxel or paclitaxel, gemcitabine with carboplatin, and eribulin. Randomization and blinding help researchers make a fairer comparison between treatment groups and reduce the effect of expectations on study assessments. This design evaluates a research question. It does not mean the investigational treatment is proven to work for an individual patient.
Who May Qualify for BNT327-05?
Publicly listed requirements provide an initial screening guide, not a final decision. Potential participants generally must be at least 18 years old and may be of any sex.
- The tumor’s PD-L1 status must render the person ineligible for the specified monospecific PD- (L)1 immunotherapy and chemotherapy combination per the study criteria.
- At least one measurable target lesion is required under RECIST version 1.1.
- A suitable archival or fresh tissue sample must be provided during screening.
- The person must have an ECOG performance status of 0 or 1, which measures how well they can carry out daily activities.
Who May Not Qualify?
Several factors can prevent enrollment. Additional exclusions can involve certain other recent cancers, higher-dose systemic corticosteroid use, live vaccines, intravenous antibiotics, surgery, transplant history, pregnancy, breastfeeding, and family-planning restrictions.
The formal screening process may also identify other medical, laboratory, medication, or timing considerations. Eligibility is determined by the trial investigators and sponsor using the complete protocol, not solely by a checklist on a public webpage.
What to Prepare Before Contacting a Trial Site
- A current diagnosis, stage, and oncology treatment summary.
- Pathology reports showing results for estrogen receptor, progesterone receptor, HER2, and PD-L1, when available.
- Recent imaging reports and scans that may document measurable disease
- A complete history of cancer treatments, including dates and reasons treatment changed or stopped.
- A list of current prescriptions, over-the-counter medicines, supplements, and steroid use.
- Information about recent surgeries, infections, hospitalizations, and vaccinations.
Where BNT327-05 Is Recruiting
BioNTech lists recruiting sites in multiple locations, including SpriThe trial investigators determine eligibilitygeles, Palo Alto, and Sacramento, California. Examples include Highlands Oncology Group, UC San Diego Moores Cancer Center, Cedars-Sinai Samuel Oschin Cancer Center, Stanford Cancer Institute, and UC Davis Health System.
Location status, appointment availability, and screening capacity may change. Confirm directly with the study contact before arranging travel, transferring records, or changing a treatment plan. BioNTech states that the pre-screening period may take up to one month, while treatment can continue for up to two years for participants who are benefiting from and tolerating study treatment.
What Evidence to Expect From the BNT327 Program
BNT327-05 is intended to collect controlled Phase 3 evidence on safety and efficacy. Its key research questions include whether adding pumitamig to chemotherapy improves cancer outcomes and whether the combination is safe. Final results from this recruiting trial are not yet available.
Earlier findings from other BNT327 studies may inform why researchers are conducting this trial, but they cannot establish the results of BNT327-05 or predict an individual’s response. Patients should review possible benefits, risks, alternatives, side effects, visit schedules, and informed consent materials. At the same time, their oncology team and study staff.
Questions to Ask Before Requesting Screening
- Is the nearest site actively recruiting and accepting pre-screening inquiries?
- Do the current ER, progesterone receptor, HER2, and PD-L1 results meet the study’s requirements?
- Can an archival tissue sample be used, or is a fresh biopsy needed?
- Which chemotherapy backbone may be considered?
- How often are visits, infusions, scans, laboratory tests, and follow-up calls expected?
- Which trial-related costs are covered, and which routine-care costs may be billed to insurance?
- What contraception, pregnancy-prevention, and caregiver-support requirements apply?
Conclusion
BioNTech’s BNT327-05 ROSETTA Breast-01 trial is a structured Phase 3 research option for a narrowly defined group of adults with advanced TNBC or certain ER-low, HER2-negative breast cancers. The next responsible step is to gather complete records, discuss the opportunity with an oncologist, and contact the official study team for an individualized screening review.